Prospective Evaluation of the Carbon Footprint and Clinical Utility of IBUS Compared to Colonoscopy and Enterography in UC and CD

May 11, 2026 updated by: Mohan Ramchandani, Asian Institute of Gastroenterology, India

Prospective Evaluation of the Carbon Footprint and Clinical Utility of Intestinal Bowel Ultrasound Compared to Colonoscopy and Enterography in Ulcerative Colitis and Crohn's Disease

Healthcare contributes approximately 4.4% of global GHG emissions, with diagnostic imaging and endoscopic services being substantial contributors. Colonoscopy and cross-sectional imaging modalities, though indispensable, are associated with high carbon emissions due to electricity use, waste, sterilisation, and transportation. IBUS, a non-invasive, real-time diagnostic modality, is increasingly validated for disease activity assessment in both UC and CD.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Healthcare contributes approximately 4.4% of global GHG emissions, with diagnostic imaging and endoscopic services being substantial contributors. Colonoscopy and cross-sectional imaging modalities, though indispensable, are associated with high carbon emissions due to electricity use, waste, sterilisation, and transportation. IBUS, a non-invasive, real-time diagnostic modality, is increasingly validated for disease activity assessment in both UC and CD. Its low energy footprint and portability make it a potential frontline tool for sustainable IBD follow-up. This study aims to quantify and compare the environmental impact and diagnostic value of IBUS versus conventional imaging strategies in real-world clinical care.

Study Type

Observational

Enrollment (Estimated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Duration: 12 months

Sample Size:

100 UC patients (Colonoscopy + IBUS), 100 CD patients (CT/MRI enterography + IBUS), Total: 200 Patients

Description

All consecutive patients undergoing endoscopy procedures with consent for procedures, during the study period will be included

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Ulcerative colitis
carbon footprint and clinical usefulness of Intestinal Bowel Ultrasound (IBUS) with standard imaging colonoscopy in patients with Ulcerative Colitis Colonoscopy+ IBUS
Crohns disease
carbon footprint and clinical usefulness of Intestinal Bowel Ultrasound (IBUS) with standard imaging CT/MRI enterography in patients with Crohn's Disease CT/MRI enterography+ IBUS

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The electricity consumed, water consumed, waste generated, and Greenhouse Gas (GHG) emissions will be analyzed
Time Frame: 12 months
The waste generated will be stratified according to the methods of disposal as Direct landfill, Incineration, and landfill or Recyclable waste. The electricity consumed, water consumed, waste generated, and Greenhouse Gas (GHG) emissions will be analyzed. The unit of emissions will remain same kgCO2e and the total emissions will then be calculated.
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Asian Institute of Gastroenterology, India

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2026

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2026

Study Registration Dates

First Submitted

December 2, 2025

First Submitted That Met QC Criteria

February 21, 2026

First Posted (Actual)

February 25, 2026

Study Record Updates

Last Update Posted (Actual)

May 12, 2026

Last Update Submitted That Met QC Criteria

May 11, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IBUS1

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Crohns Disease

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe